[go: up one dir, main page]

PT3679034T - Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica - Google Patents

Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica

Info

Publication number
PT3679034T
PT3679034T PT187621115T PT18762111T PT3679034T PT 3679034 T PT3679034 T PT 3679034T PT 187621115 T PT187621115 T PT 187621115T PT 18762111 T PT18762111 T PT 18762111T PT 3679034 T PT3679034 T PT 3679034T
Authority
PT
Portugal
Prior art keywords
methylpropan
isoxazol
pyrazol
ifn
derivatives
Prior art date
Application number
PT187621115T
Other languages
English (en)
Original Assignee
Immunic Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunic Ag filed Critical Immunic Ag
Publication of PT3679034T publication Critical patent/PT3679034T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT187621115T 2017-09-06 2018-09-06 Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica PT3679034T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189652 2017-09-06

Publications (1)

Publication Number Publication Date
PT3679034T true PT3679034T (pt) 2022-08-29

Family

ID=59799324

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187621115T PT3679034T (pt) 2017-09-06 2018-09-06 Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para tratamento de doenças autoimunes e da inflamação crónica

Country Status (26)

Country Link
US (1) US11292788B2 (pt)
EP (2) EP4074708A1 (pt)
JP (2) JP2020532575A (pt)
KR (1) KR20200069299A (pt)
CN (1) CN111433202A (pt)
AU (1) AU2018330633C1 (pt)
CA (1) CA3074891A1 (pt)
DK (1) DK3679034T3 (pt)
ES (1) ES2925538T3 (pt)
HR (1) HRP20221042T1 (pt)
HU (1) HUE059822T2 (pt)
IL (1) IL273064B2 (pt)
LT (1) LT3679034T (pt)
MA (1) MA50069B1 (pt)
MD (1) MD3679034T2 (pt)
MX (1) MX2020002571A (pt)
PH (1) PH12020500461A1 (pt)
PL (1) PL3679034T3 (pt)
PT (1) PT3679034T (pt)
RS (1) RS63532B1 (pt)
SG (1) SG11202001409UA (pt)
SI (1) SI3679034T1 (pt)
SM (1) SMT202200343T1 (pt)
UA (1) UA126689C2 (pt)
WO (1) WO2019048541A1 (pt)
ZA (1) ZA202001179B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433202A (zh) * 2017-09-06 2020-07-17 埃慕尼克股份公司 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物
US20240368145A1 (en) 2021-07-09 2024-11-07 Immunic Ag Methods for treating cancer
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
US20250243190A1 (en) 2022-04-14 2025-07-31 Immunic Ag New deuterated rorgamma/rorgammat inverse agonists
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN119192167B (zh) * 2024-11-28 2025-03-21 英矽智能科技(上海)有限公司 一类抑制il-17的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2668183T3 (pl) * 2011-01-28 2018-10-31 Immunic Ag Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
US8592456B2 (en) * 2011-01-28 2013-11-26 4Sc Discovery Gmbh IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
CN111433202A (zh) * 2017-09-06 2020-07-17 埃慕尼克股份公司 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物

Also Published As

Publication number Publication date
AU2018330633B2 (en) 2021-02-25
KR20200069299A (ko) 2020-06-16
RU2020112319A3 (pt) 2022-02-07
US20210061796A1 (en) 2021-03-04
HUE059822T2 (hu) 2022-12-28
ES2925538T3 (es) 2022-10-18
MA50069A (fr) 2021-05-05
BR112020004332A2 (pt) 2020-09-08
SI3679034T1 (sl) 2022-11-30
RU2020112319A (ru) 2021-10-06
EP4074708A1 (en) 2022-10-19
LT3679034T (lt) 2022-09-12
HRP20221042T1 (hr) 2022-11-11
AU2018330633C1 (en) 2022-02-24
DK3679034T3 (da) 2022-08-29
CA3074891A1 (en) 2019-03-14
IL273064B2 (en) 2023-06-01
MX2020002571A (es) 2020-10-01
WO2019048541A1 (en) 2019-03-14
RS63532B1 (sr) 2022-09-30
IL273064A (en) 2020-04-30
MD3679034T2 (ro) 2022-10-31
ZA202001179B (en) 2023-03-29
JP2023052060A (ja) 2023-04-11
MA50069B1 (fr) 2023-08-31
UA126689C2 (uk) 2023-01-11
SG11202001409UA (en) 2020-03-30
PL3679034T3 (pl) 2022-11-14
NZ761897A (en) 2023-10-27
CN111433202A (zh) 2020-07-17
PH12020500461A1 (en) 2021-01-11
JP2020532575A (ja) 2020-11-12
AU2018330633A1 (en) 2020-03-05
US11292788B2 (en) 2022-04-05
EP3679034A1 (en) 2020-07-15
SMT202200343T1 (it) 2022-11-18
EP3679034B1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL273064A (en) 1-(4-(Isoxazol-5-yl)-H1-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as IL-17 and IFN-gamma suppressors for the treatment of autoimmune diseases and chronic inflammation
HUS2400019I1 (hu) KRas G12C inhibotorok
IL312670B2 (en) Imidazole-containing ALK2 kinase inhibitors
IL275948A (en) History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses
IL254736B (en) Imidazole [1,2-c]pyrimidine derivative compounds, 1LSD inhibitors, pharmaceutical compound comprising them and use for cancer treatment
IL273585A (en) Therapeutic methods related to HSP90 inhibitors
EP3247353A4 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
LT3464271T (lt) Pirazolo dariniai kaip plazmos kalikreino inhibitoriai
EP3432927A4 (en) TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
HUE062460T2 (hu) TRPC6 inhibitorok
IL279452B (en) Pyrazole history as malt1 inhibitors
IL279453B (en) Pyrazole history as malt1 inhibitors
IL281371A (en) Indazole carboxamides as kinase inhibitors
IL268565B (en) A history of pyrazoles as bromodomain inhibitors
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors
GB201702160D0 (en) Inhibitors for use in therapy
IL279348A (en) Pyrazole and imidazole compounds as IL-17 and ROR gamma tracers
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
PL3364971T3 (pl) Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu
HK40027555A (en) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation
HK40033924A (en) Protein kinase c inhibitors for treatment of uveal melanoma
HK40052012A (en) Usp19 inhibitors for use in therapy
HK40058961A (en) Methods of treatment of cancer comprising cdc7 inhibitors